The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...

This content was published on Oct 24, 2024 On Thursday, the Swiss Federal Railways presented its first fully renovated InterCity tilting train (ICN). Read more: Swiss railways presents first fully ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...

On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) ...

Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...